Get the Stockscreener App
2.385
4.15%
0.095
Aytu Biopharma Inc stock is traded at $2.385, with a volume of 172.52K.
It is up +4.15% in the last 24 hours and up +53.87% over the past month.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.
See More
Previous Close:
$2.29
Open:
$2.31
24h Volume:
172.52K
Relative Volume:
0.13
Market Cap:
$18.13M
Revenue:
$93.76M
Net Income/Loss:
$-13.68M
P/E Ratio:
-0.9068
EPS:
-2.63
Net Cash Flow:
$8.77M
1W Performance:
+12.50%
1M Performance:
+53.87%
6M Performance:
+34.37%
1Y Performance:
-16.32%
1-Day Range:
$2.27
$2.45
1-Week Range:
$2.04
$2.45
52-Week Range:
$0.95
$2.96
Aytu Biopharma Inc Stock (AYTU) Company Profile
Name
Aytu Biopharma Inc
Sector
Phone
(720) 437-6580
Address
7900 E. UNION AVENUE, DENVER
Compare AYTU with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AYTU
Aytu Biopharma Inc
|
2.385 | 18.13M | 93.76M | -13.68M | 8.77M | -2.63 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.99 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.18 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.25 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.01 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-30-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-29-20 | Initiated | H.C. Wainwright | Buy |
Aytu Biopharma Inc Stock (AYTU) Latest News
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Decline in Short Interest - Defense World
Insider Spends US$100k Buying More Shares In Aytu BioPharma - simplywall.st
CEO & Director of Aytu BioPharma Joshua Disbrow Buys 77% More Shares - Yahoo Finance
Transcript : Aytu BioPharma, Inc.Special Call - MarketScreener
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharm - GuruFocus
Insider Buying: Jarrett Disbrow Acquires Shares of Aytu BioPharma Inc (AYTU) - GuruFocus
Aytu Biopharma chief business officer buys $24,999 in stock By Investing.com - Investing.com South Africa
Aytu Biopharma chief business officer buys $24,999 in stock - Investing.com Australia
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock By Investing.com - Investing.com Canada
Aytu Biopharma CEO Joshua Disbrow acquires $99,999 in stock - Investing.com Australia
AYTU BIOPHARMA Executives Increase Stake in Company - TradingView
Aytu BioPharma Announces Closing of Upsized At the Market Public - GuruFocus
Aytu BioPharma Announces Closing of Upsized At the Market Public Offering of Common Stock with Full Exercise of Overallotment and Conference Call to Discuss First-in-Class Antidepressant EXXUA(TM) Opportunity and Commercialization Plan - ACCESS Newswire
Breakthrough: First Depression Drug Without Sexual Side Effects Gets $16.6M Backing for Q4 Launch - Stock Titan
Aytu BioPharma to commercialise Exxua for MDD in the US - Yahoo Finance
Aytu BioPharma (AYTU) Announces Upsized Public Offering to Fund - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug By Investing.com - Investing.com South Africa
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer P - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYT - GuruFocus
AYTU Increases Common Stock Offering to 9.6 Million Shares | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of - GuruFocus
Aytu BioPharma secures exclusive rights to new MDD drug - Investing.com
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock | AYTU Stock News - GuruFocus
Aytu BioPharma (AYTU) Secures Exclusive Deal for U.S. Launch of Exxua Tablets | AYTU Stock News - GuruFocus
AytuBioPharma (AYTU) Secures Exclusive Rights to Commercialize EXXUA in the U.S. | AYTU Stock News - GuruFocus
Aytu BioPharma Announces Exclusive Agreement with Fabre-Kramer Pharmaceuticals to Commercialize First-in-Class Antidepressant EXXUA(TM) (gepirone) Extended-Release Tablets in the United States | AYTU - GuruFocus
Aytu BioPharma Announces At the Market Pricing of $14.4 Million Upsized Public Offering of Common Stock - ACCESS Newswire
Aytu BioPharma Secures $14.4M Financing: Major Funds Back EXXUA Depression Drug Commercialization - Stock Titan
New Antidepressant EXXUA Enters $22B Market Without Sexual Side Effects | AYTU Stock News - Stock Titan
AYTU: Lake Street Takes Role as Sole Book-Running Manager | AYTU Stock News - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Significant Growth in Short Interest - Defense World
Aytu signals ongoing portfolio expansion opportunities as Q3 2025 revenue surges 32% - MSN
Aytu BioPharma Ranked Number 178 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500(TM) - ACCESS Newswire
Aytu BioPharma (AYTU) Reports Significant Revenue Growth in Q3 2 - GuruFocus
Aytu BioPharma, Inc. (NASDAQ:AYTU) Q3 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: Aytu BioPharma Q2 2025 sees revenue dip, strategic shifts - MSN
Aytu BioPharma Third Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results | AYTU Stock News - GuruFocus
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings: EPS of $0.21 Beats E - GuruFocus
Why Boot Barn Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Aytu BioPharma Inc (AYTU) Q3 2025 Earnings Call Highlights: Stro - GuruFocus
Aytu BioPharma Reports Strong Q3 2025 Earnings - TipRanks
Aytu Biopharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Aytu BioPharma (AYTU) Reports Strong Q3 Earnings Beat - GuruFocus
Earnings call transcript: Aytu BioPharma sees Q3 revenue surge, stock jumps - Investing.com India
Aytu BioPharma Reports Fiscal 2025 Third Quarter Results - TradingView
Transcript : Aytu BioPharma, Inc., Q3 2025 Earnings Call, May 14, 2025 - marketscreener.com
Aytu BioPharma Reports Fiscal 2025 Third Quarter Operational and Financial Results - ACCESS Newswire
We Think Some Shareholders May Hesitate To Increase Aytu BioPharma, Inc.'s (NASDAQ:AYTU) CEO Compensation - simplywall.st
Aytu BioPharma to Report Fiscal 2025 Third Quarter Operational a - GuruFocus
Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference - ACCESS Newswire
Aytu Biopharma Inc Stock (AYTU) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aytu Biopharma Inc Stock (AYTU) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Disbrow Joshua R. | Chief Executive Officer |
Jun 09 '25 |
Buy |
1.50 |
66,666 |
99,999 |
153,257 |
| Disbrow Joshua R. | Chief Executive Officer |
Feb 28 '25 |
Buy |
1.30 |
15,000 |
19,500 |
86,591 |
0.54%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):